QurAlis’ selective KCNQ2/3 opener, QRA-244, demonstrates up to 20-fold increase in potency and dramatic reduction in side effects compared to retigabine

BY      |     December 12, 2020

QurAlis Corporation, a biotech company focused on developing precision medicines for amyotrophic lateral sclerosis (ALS) and other neurologic diseases, announced the results of extensive pre-clinical studies on its lead program, QRA-244, for ALS patients.

QRA-244, a Kv7.2/7.3 ion channel opener, has been shown in preclinical studies to have strong potential to control motor neuron hyperexcitability-induced excitotoxicity with significantly fewer side effects than other drug candidates. QRA-244 has demonstrated comparable effects to the anticonvulsant medication retigabine (ezogabine) at up to 20-fold lower concentration in motor neurons differentiated from patient-derived iPSCs. Importantly, QRA-244 showed dramatic reductions in side effects associated with retigabine including fatigue/somnolence, dizziness and bladder retention in head-to-head pre-clinical studies.

Reduced off-target side effects make QRA-244 a strong drug candidate to treat hyperexcitability-induced disease progression in ALS patients.

QurAlis plans to initiate first-in-human studies of QRA-244 at the end of 2021/beginning of 2022.

Read the press release here.

Read more about QurAlis here.

Image by Gerd Altmann from Pixabay

Comments? Questions? Suggestions?

If you have any comments, questions or suggestions concerning this article, feel free to email me at
Alternatively, you can leave your comments on LinkedIn or Twitter.